Navigation Links
Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
Date:7/14/2011

g the influenza A H1N1, H5N1, H3N2, H2N2 subtypes as well as influenza B with the goal of developing a universal influenza vaccine.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or support
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
2. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
3. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
4. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
5. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
6. Inovio Pharmaceuticals to Present at Investor Conferences
7. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
8. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
9. Inovio Pharmaceuticals to Present at Scientific Conferences
10. Inovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... DIEGO, Sept. 27 Clinicians from three U.S. hospitals ... IV catheter-related bloodstream infections (CRBSI). Data analyzed and presented ... Springs, Ark.; Bethesda North Hospital in Cincinnati; and the ... virtually eliminated such infections, which annually kill some 62,500 ...
... The Colorado Institute for Drug, Device and Diagnostic Development ... solicitation announced in February.  The announcement is made by ... Sophono, Inc., is receiving $600,000 for its Alpha 1 ... is receiving $300,000 for its universal flu vaccine under ...
Cached Medicine Technology:Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 2Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 3Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 4The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K 2
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... , PORTLAND, Ore., July 24 Kim-Chi Vu, M.D., ... FDA-approved microsphere-enhanced collagen filler for the correction of smile lines. Dr. Vu ... its proven success and effectiveness for the long lasting correction of wrinkles. ... is a great product for many reasons. First and foremost it ...
... Thousands respond to the world evangelist,s proclamation of the Good News ... , KIGALI, Rwanda, July 24 ... million people in 100 days, the people of Rwanda continue the ... strong future. Through Kigali Festival with Andrew Palau on July 17-18, ...
... SANTA MONICA, Calif., July 24 The following advisory was issued by Consumer Watchdog: , ... for CIGNA health insurance , , When : , ... : , Hilton , Civil Justice Foundation Breakfast of Champions ... San Francisco, CA 94102 , , What : ...
... LOS ANGELES, July 24 Good vision can be directly ... learning a child does occurs through his eyes and approximately 1 in ... , Does your child have normal, healthy vision needed ... a pediatric ophthalmologist, optometrist or pediatrician? , , ...
... both conditions among Vietnam vets , FRIDAY, July 24 (HealthDay ... were sprayed far and wide by the U.S. military during ... heart disease and Parkinson,s. , An Institute of Medicine ... elevated risk for these two conditions among soldiers who served ...
... , SAN FRANCISCO, July 24 The ... one of over 100 Affiliates nationwide dedicated to putting an end to ... support Bay Area breast health education and breast cancer screening and treatment ... Bay Area Affiliate,s local fundraising efforts, such as the Komen ...
Cached Medicine News:Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Rwanda Genocide 100-Day Commemoration Culminates With Kigali Festival With Andrew Palau 2Health News:CIGNA Whistleblower Calls for More Heath Insurance Accountability in Heath Care Reform 2Health News:Back-to-School Health: Are Your Child's Eyes Ready for the Classroom? 2Health News:Back-to-School Health: Are Your Child's Eyes Ready for the Classroom? 3Health News:Agent Orange Linked to Parkinson's, Heart Disease 2Health News:Agent Orange Linked to Parkinson's, Heart Disease 3Health News:Agent Orange Linked to Parkinson's, Heart Disease 4Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 2Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 3Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 4
... and Evisceration. The new MEDPOR ... standard MEDPOR Spheres with a bioactive ... mixed throughout the sphere structure, promotes ... MEDPOR PLUS sphere., ,MEDPOR is a ...
... Cadwell's custom bars have a large ... machined contacts (spaced 3 centimeters center-to-center) ... of repeated cleaning. Polarity indicators are ... snap-on handle fits our bar electrode ...
... Cadwell's custom bars have a ... solid, machined contacts (spaced 3 centimeters ... tear of repeated cleaning. Polarity indicators ... convenient, snap-on handle fits our bar ...
... IOL is the first lens of its kind ... the reduction or elimination of myopia in adults ... and in patients aged 21 and over. ... procedures performed worldwide, results prove that the Verisyse ...
Medicine Products: